Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...